ArticleCancer gene therapy2026
Study on the expression, prognostic value, and molecular mechanisms of TIMP1 in glioma.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TIMP1 exerts oncogenic effects in multiple malignant tumors, yet its specific biological functions and molecular mechanisms in glioma remain incompletely elucidated. This study systematically investigated the expression level, clinical prognostic significance and underlying functional mechanisms of TIMP1 in glioma. Pan-cancer analysis verified that TIMP1 is abnormally overexpressed across a wide range of tumor tissues, with particularly prominent upregulation observed in glioma. Its high expression is closely correlated with malignant clinicopathological phenotypes of glioma and serves as an effective indicator of poor overall survival for patients. In vitro functional experiments confirmed that elevated TIMP1 expression accelerates the proliferation, migration and invasion of glioma cells. Mechanistic studies revealed that TIMP1 sustains the malignant progression of glioma by regulating multiple core extracellular matrix genes and activating extracellular matrix signaling pathways. Collectively, TIMP1 facilitates the malignant evolution of glioma via mediating extracellular matrix signaling cascades, and it holds great promise as a novel molecular biomarker for clinical prognostic evaluation and a potential therapeutic target for glioma.
Identifiers
42693179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.